• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

AOP Orphan Pharmaceuticals - Articles and news items

Blue & White Pills

AOP Orphan strengthens core CNS specialty business with high promise in movement disorder treatments

Industry news / 19 June 2015 / AOP Orphan Pharmaceuticals AG

AOP Orphan Pharmaceuticals AG has announced the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member state…